|
Novartis' Cosentyx is first and only IL-17A inhibitor to potentially modify the course of psoriasis
|
22 March 2017 |
|
New analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes
|
20 March 2017 |
|
Sandoz announces winners of inaugural Healthcare Access Challenge #SandozHACk
|
13 March 2017 |
|
Novartis' Cosentyx shows almost all psoriasis patients rapidly regain skin clearance following a treatment pause
|
07 March 2017 |
|
Novartis drug Zykadia receives FDA Priority Review for first-line use in patients with ALK+ metastatic NSCLC
|
23 February 2017 |
|
Novartis delivered solid 2016 performance
|
25 January 2017 |
|
Novartis invests in next generation therapies to reduce cardiovascular risk in patients with underlying lipid disorders
|
06 January 2017 |
|
Novartis announces exclusive option, collaboration and license agreement with Conatus to develop new oral treatments for chronic liver diseases
|
19 December 2016 |
|
Novartis bolsters innovative dermatology portfolio through acquisition of Ziarco Group Limited
|
16 December 2016 |
|
Novartis launches SMS for Life 2.0 in Nigeria to help improve access to essential medicines
|
12 December 2016 |